由西格玛-1受体对抗剂直接抑制GIRK通道的结构决定因素
Chang Liu1, I-Shan Chen2, Michihiro Tateyama1
1Division of Biophysics and Neurobiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Japan; Program of Physiological Sciences, Field of Life Science, Department of Advanced Studies, SOKENDAI (The Graduate University for Advanced Studies), Hayama, Japan.
BD1047二胺直接抑制G蛋白门内向整流器K+ (GIRK) 通道,特别是GIRK4,独立于西格玛-1受体活性. 这揭示了一个新的GIRK通道抑制剂和GIRK4相关疾病的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- G蛋白门内向整流器K+ (GIRK) 通道对于调节神经元和心肌细胞刺激性至关重要.
- BD1047二酸被称为西格玛-1受体 (S1R) 抗剂.
- 最初的观察表明BD1047可能会通过S1R.影响GIRK通道.
研究的目的:
- 调查BD1047对GIRK频道的直接影响.
- 确定BD1047与GIRK频道相互作用的结构基础.
- 探索BD1047作为GIRK通道调节的潜在药理学工具.
主要方法:
- 在Xenopus卵细胞和孤立的老鼠心房肌细胞中进行电生理学记录.
- 在GIRK2和GIRK4通道的局部定向突变和仿真构造.
- 分子对接分析. 分子对接分析.
- 用GIRK通道激活剂ivermectin进行竞争测试.
主要成果:
- BD1047以电压独立的方式直接抑制了GIRK电流.
- 与GIRK2.2相比,BD1047表现出更强的GIRK4抑制.
- 在GIRK4中,特定的残留物 (Leu77, Leu84, Glu147) 被确定为BD1047结合的关键.
- 在GIRK4上的Leu77结合Ivermectin与BD1047.7.竞争.
结论:
- BD1047是一种新的,GIRK通道的直接抑制剂,偏好GIRK4.
- GIRK4的N端区域和孔形成域是BD1047相互作用的关键区域.
- 这项研究为开发涉及GIRK4通道疾病的治疗方法提供了一种新的药理学剂和见解.
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
GPCR Desensitization
GPCRs Regulate Adenylyl Cylase Activity
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
G-Protein Gated Ion Channels
Sensory...


